These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 31383376)

  • 21. Causal Deep Learning for the Detection of Adverse Drug Reactions: Drug-Induced Acute Kidney Injury as a Case Study.
    Dimitsaki S; Natsiavas P; Jaulent MC
    Stud Health Technol Inform; 2024 Aug; 316():803-807. PubMed ID: 39176914
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Making Sense of Pharmacovigilance and Drug Adverse Event Reporting: Comparative Similarity Association Analysis Using AI Machine Learning Algorithms in Dogs and Cats.
    Xu X; Mazloom R; Goligerdian A; Staley J; Amini M; Wyckoff GJ; Riviere J; Jaberi-Douraki M
    Top Companion Anim Med; 2019 Dec; 37():100366. PubMed ID: 31837760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Artificial intelligence in pharmacovigilance: Do we need explainability?
    Hauben M
    Pharmacoepidemiol Drug Saf; 2022 Dec; 31(12):1311-1316. PubMed ID: 35747938
    [No Abstract]   [Full Text] [Related]  

  • 24. "Artificial Intelligence" for Pharmacovigilance: Ready for Prime Time?
    Ball R; Dal Pan G
    Drug Saf; 2022 May; 45(5):429-438. PubMed ID: 35579808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Artificial Intelligence in Pharmacovigilance and COVID-19.
    Bhardwaj K; Alam R; Pandeya A; Sharma PK
    Curr Drug Saf; 2023; 18(1):5-14. PubMed ID: 35382726
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Artificial Intelligence and Data Mining for the Pharmacovigilance of Drug-Drug Interactions.
    Hauben M
    Clin Ther; 2023 Feb; 45(2):117-133. PubMed ID: 36732152
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advancing drug safety science by integrating molecular knowledge with post-marketing adverse event reports.
    Soldatos TG; Kim S; Schmidt S; Lesko LJ; Jackson DB
    CPT Pharmacometrics Syst Pharmacol; 2022 May; 11(5):540-555. PubMed ID: 35143713
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Review of the Methods to Obtain Paediatric Drug Safety Information: Spontaneous Reporting and Healthcare Databases, Active Surveillance Programmes, Systematic Reviews and Meta-analyses.
    Gentili M; Pozzi M; Peeters G; Radice S; Carnovale C
    Curr Clin Pharmacol; 2018; 13(1):28-39. PubMed ID: 29412117
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Artificial Intelligent Context-Aware Machine-Learning Tool to Detect Adverse Drug Events from Social Media Platforms.
    Roosan D; Law AV; Roosan MR; Li Y
    J Med Toxicol; 2022 Oct; 18(4):311-320. PubMed ID: 36097239
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety of medicines and vaccines - building next generation capability.
    Bate A; Stegmann JU
    Trends Pharmacol Sci; 2021 Dec; 42(12):1051-1063. PubMed ID: 34635346
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Dealing with adverse drug reactions in dentistry. Procedures on encountering adverse drug reactions and goal of the Swiss Pharmacovigilance system].
    Egger SS; Krähenbühl S; Schlienger RG
    Schweiz Monatsschr Zahnmed; 2005; 115(12):1209-18. PubMed ID: 16408825
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adverse Drug Reaction Case Safety Practices in Large Biopharmaceutical Organizations from 2007 to 2017: An Industry Survey.
    Stergiopoulos S; Fehrle M; Caubel P; Tan L; Jebson L
    Pharmaceut Med; 2019 Dec; 33(6):499-510. PubMed ID: 31933240
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Artificial Intelligence in Pharmacovigilance: An Introduction to Terms, Concepts, Applications, and Limitations.
    Aronson JK
    Drug Saf; 2022 May; 45(5):407-418. PubMed ID: 35579806
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pharmacovigilance of vaccines].
    Autret-Leca E; Bensouda-Grimaldi L; Jonville-Béra AP; Beau-Salinas F
    Arch Pediatr; 2006 Feb; 13(2):175-80. PubMed ID: 16343870
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Innovation in Pharmacovigilance: Use of Artificial Intelligence in Adverse Event Case Processing.
    Schmider J; Kumar K; LaForest C; Swankoski B; Naim K; Caubel PM
    Clin Pharmacol Ther; 2019 Apr; 105(4):954-961. PubMed ID: 30303528
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug safety in Africa: a review of systems and resources for pharmacovigilance.
    Ndagije HB; Walusimbi D; Atuhaire J; Ampaire S
    Expert Opin Drug Saf; 2023; 22(10):891-895. PubMed ID: 37676033
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Computational and artificial intelligence-based approaches for drug metabolism and transport prediction.
    Dudas B; Miteva MA
    Trends Pharmacol Sci; 2024 Jan; 45(1):39-55. PubMed ID: 38072723
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Artificial Intelligence Based on Machine Learning in Pharmacovigilance: A Scoping Review.
    Kompa B; Hakim JB; Palepu A; Kompa KG; Smith M; Bain PA; Woloszynek S; Painter JL; Bate A; Beam AL
    Drug Saf; 2022 May; 45(5):477-491. PubMed ID: 35579812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.